Trial Profile
Efficacy and Safety of Ombitasvir plus Paritaprevir/r combination regimen for Hepatitis C infected patients with immune disorders
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jan 2020
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 07 Jan 2020 Status changed from recruiting to completed.
- 29 Sep 2016 Status changed from not yet recruiting to recruiting.
- 26 May 2016 New trial record